Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

This ASX healthcare company just delivered a clinical update today. Here is why investors are paying close attention.

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of ...

Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for milestone payments under existing collaboration  Scott ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

An Alabama Senate committee unanimously approved a bill Wednesday morning that would require health insurance companies to ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

MISSISSAUGA, ON / ACCESS Newswire / January 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...